Download PDF
Thromb Haemost 1995; 74(03): 842-847
DOI: 10.1055/s-0038-1649834
Original Article
Clinical Studies
Schattauer GmbH Stuttgart

Environmental and Genetic Factors in Relation to Elevated Circulating Levels of Plasminogen Activator Inhibitor-1 in Caucasian Patients with Non-Insulin-Dependent Diabetes Mellitus

Michael W Mansfield
The Diabetes and Thrombosis Research Group, Division of Medicine, School of Medicine, University of Leeds, UK
,
Max H Stickland
The Diabetes and Thrombosis Research Group, Division of Medicine, School of Medicine, University of Leeds, UK
,
Peter J Grant
The Diabetes and Thrombosis Research Group, Division of Medicine, School of Medicine, University of Leeds, UK
› Author Affiliations
Further Information

Publication History

Received 21 February 1995

Accepted after revision 05 May 1995

Publication Date:
09 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

To investigate the interaction of metabolic and genetic factors in relation to PAI-1, genotype was determined at a 4G/5G polymorphism in the PAI-1 gene promoter and at a Hind III RFLP of the PAI-1 gene in 189 Caucasian NIDDM patients. PAI-1 levels were equivalent in each genotype group and PAI-1 activity correlated with fasting insulin (r = 0.45), triglyceride (r = 0.39) body mass index (r = 0.44), cholesterol (r = 0.17) and glucose (r = 0.15). The regression slope (B) of PAI-1 activity on triglycerides was steeper in the 4G/4G group than the other two groups: 4G/4G B = 0.91, r = 0.62; 4G/5G B = 0.36, r = 0.27; 5G/5G B = 0.31, r = 0.29 (difference between slopes p = 0.02) and the association between PAI-1 activity and glucose remained only in the 4G/4G group (r = 0.35). These results confirm the association of PAI-1 levels with the features of insulin resistance and indicate that the association between PAI-1 levels and both triglyceride and glucose is influenced by genotype in the region of the PAI-1 gene promoter.

 

  • References

  • 1 Kannal WB, McGee DL. Diabetes and cardiovascular disease, the Framingham Study. Jama 1979; 241: 2035-2038
    CrossrefPubMedGoogle Scholar
  • 2 Multiple Risk Factor Intervention Trial (MRFIT) Research Group. Multiple risk factor intervention trial: risk factor changes and mortality results. JAMA 1982; 248: 1465-1477
    CrossrefPubMedGoogle Scholar
  • 3 Pydörälä K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease. Results from two population studies in Finland Diabetes care 1979; 2: 131-141
    PubMedGoogle Scholar
  • 4 Walmsley D, Hampton KK, Grant PJ. Contrasting fibrinolytic responses in type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes. Diabet Med 1991; 8: 954-959
    CrossrefPubMedGoogle Scholar
  • 5 Auwerx J, Bouillon R, Cullen D, Geboers J. Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis 1988; 8: 68-72
    CrossrefPubMedGoogle Scholar
  • 6 Garefa Frade LJ, de la CalleH, Torrado MC, Lara JL, Cuellar L, Garcia Avello A. Hypofibrinolysis associated with vasculopathy in non insulin dependent diabetes mellitus. Thromb Res 1990; 59: 5l-59
    PubMedGoogle Scholar
  • 7 Gough SC L, Rice PJ S, McCormack L, Chapman C, Grant PJ. The relationship between plasminogen activator inhibitor-1 and insulin resistance in newly diagnosed type 2 diabetes mellitus. Diabet Med 1993; 10: 638-642
    CrossrefPubMedGoogle Scholar
  • 8 Juhan-Vague I, Roul C, Alessi MC, Ardissone JP, Heim M, Vague P. Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients-relationship with plasma insulin. Thromb Haemost 1989; 61: 370-373
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Smith EB. Fibrinogen, fibrin and fibrin degradation products in relation to atherosclerosis. Clin Haematol 1986; 15: 355-370
    PubMedGoogle Scholar
  • 10 Landin K, Stigendal L, Eriksson E, Krotkiewski M, Risberg B, Tengborn L, Smith U. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism 1990; 39: 1044-1048
    CrossrefPubMedGoogle Scholar
  • 11 Landin K, Tengborn L, Smith U. Elevated fibrinogen and plasminogen activator inhibitors (PAN) in hypertension are related to metabolic risk factors for cardiovascular disease. J Int Med 1990; 227: 273-278
    CrossrefPubMedGoogle Scholar
  • 12 Potter van Loon BJ, Kluft K, Raadder JK, Blankenstein MA, Meinders AE. The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism 1993; 42: 945-949
    CrossrefPubMedGoogle Scholar
  • 13 Juhan-Vague I, Alessi MC, Joly P, Thirion W, Vague P, Declerck PJ, Serradimigni A, Collen D. Plasma plasminogen activator inhibitor-1 in angina pectoris. Influence of plasma insulin and acute phase-response Arteriosclerosis 1989; 9: 362-367
    CrossrefPubMedGoogle Scholar
  • 14 Juhan-Vague I, Vague P, Alessi MC, Badier C, Valadier J, Aillaud MF, Atlan C. Relationships between plasma insulin, triglyceride, body mass index and plasminogen activator inhibitor 1. Diabete Metab 1987; 13: 331-336
    PubMedGoogle Scholar
  • 15 Mehta J, Mehta P, Lawson D, Saldeen T. Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: Correlations with age and triglyceride concentrations. J Am Coll Cardiol 1987; 9: 263-268
    CrossrefPubMedGoogle Scholar
  • 16 Hamsten A, de Faire U, Walldius G, Dahlén G, Szamosi A, Landou C, Blombäck M, Wiman B. Plasminogen activator inhibitor in plasma: Risk for recurrent myocardial infarction. Lancet 1987; 2: 3-9
    PubMedGoogle Scholar
  • 17 Sundell IB, Nilsson TK, Hallmans G, Hellsten G, Dahlen GH. Interrelationships between plasma levels of plasminogen activator inhibitor, tissue plasminogen activator, lipoprotein(a), and established cardiovascular risk factors in a North Swedish population. Atherosclerosis 1989; 80: 9-16
    CrossrefPubMedGoogle Scholar
  • 18 Juhan-Vague I, Valadier J, Alessi MC, Aillaud MF, Ansaldi J, Philip-Joet C, Holvoet P, Serradimigni A, Collen D. Deficient t-PA release in patients with spontaneous or recurrent deep venous thrombosis. Thromb Haemost 1987; 57: 67-72
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Mussoni L, Mannucci L, Sirtori M, Camera M, Maderna P, Sironi L, Tremoli E. Hypertriglyceridemia and regulation of fibrinolytic activity. Arterioscler Thromb 1992; 12: 19-27
    CrossrefPubMedGoogle Scholar
  • 20 Maiello M, Boeri D, Podesta F, Cagliero E, Vichi M, Odetti P, Adezati L, Lorenzi M. Increased expression of tissue plasminogen activator and its inhibitor and reduced fibrinolytic potential of human endothelial cells cultured in elevated glucose. Diabetes 1992; 41: 1009-1015
    CrossrefPubMedGoogle Scholar
  • 21 Nordt TK, Klassen KJ, Schneider DJ, Sobel BE. Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis. Arterioscler Thromb 1993; 13: 1822-1828
    CrossrefPubMedGoogle Scholar
  • 22 Gunnarsson R, Nyman D, Wålinder O, üstman J. Fibrinolytic activity and diabetes control - Evidence for a relationship. A preliminary report Acta Med Scand Suppl 1980; 639: 23-24
    PubMedGoogle Scholar
  • 23 van Wersch JW J, Donders SH J, Westerhuis LWJJM, Venekamp WJRR. Microalbuminuria in diabetic patients: relationship to lipid, glycomctabolic, coagulation and fibrinolysis parameters. Eur J Clin Chem Clin Biochem 1991; 29: 493-498
    PubMedGoogle Scholar
  • 24 Dawson S, Hamsten A, Wiman B, Henney A, Humphries S. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb 1991; 2: 183-190
    PubMedGoogle Scholar
  • 25 Dawson S, Wiman B, Hamsten A, Green F, Humphries S, Henney A. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-I) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993; 268: 10739-10745
    PubMedGoogle Scholar
  • 26 Mansfield MW, Stickland MH, Carter A, Grant PJ. Polymorphisms of the plasminogen activator inhibitor-1 gene in type I and type 2 diabetes and in patients with diabetic retinopathy. Thromb Haemost 1994; 71: 731-736
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 Falk G, Svensson II, Almqvist A, Wiman B. Allele specific PCR for detection of a sequence polymorphism in the promoter region of the plasminogen activator inhibitor-1 (PAI-I) gene (abstract). Fibrinolysis 1994; 8 Suppl (Suppl. 01) 45
    PubMedGoogle Scholar
  • 28 Armitage P, Berry G. Statistical methods in medical research. 2nd. Edn Blackwell; Oxford,UK,: 1987. pp 273-282
    Google Scholar
  • 29 Juhan-Vague I, Alessi MC. Plasminogen activator inhibitor 1 and athero-thrombosis. Thromb Haemost 1993; 70: 138-143
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Alessi MC, Juhan-Vague I, Kooistra T, Declerck PJ, Collen D. Insulin stimulates the synthesis of plasminogen activator inhibitor-1 by the human hepatocellular cell line Hep G2. Thromb Haemost 1988; 60: 491-494
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Grant PJ, Ruegg M, Medcalf RL. Basal expression and insulin-mediated induction of PAI-1 mRNA in Hep G2 cells. Fibrinolysis 1991; 5: 81-86
    PubMedGoogle Scholar
  • 32 Kooistra T, Bosma PJ, Tons HAM, van den Berg AP, Meyer P, Princen HMG. Plasminogen activator inhibitor 1 Biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes. Thromb Haemost 1989; 62: 723-728
    Article in Thieme ConnectPubMedGoogle Scholar
  • 33 Grant PJ, Kruithof EK O, Felley CP, Felber JP, Bachmann F. Short term infusions of insulin, triacylglycerol and glucose do not cause acute increases in plasminogen activator inhibitor-1 concentrations in man. Clin Sci 1990; 79: 513-516
    CrossrefPubMedGoogle Scholar
  • 34 Potter van Loon BJ, deBart AC W, Radder JK, Frölich M, Kluft C, Meinders AE. Acute exogenous hyperinsulinaemia does not result in elevation of plasma plasminogen activator inhibitor-1 (PAI-1) in humans. Fibrinolysis 1990; (Suppl. 04) Suppl 2: 93-94
    PubMedGoogle Scholar
  • 35 Landin K, Tengborn L, Chmielewska J, von Schenck H, Smith U. The acute effect of insulin on tissue plasminogen activator and plasminogen activator inhibitor in man. Thromb Haemost 1991; 65: 130-133
    Article in Thieme ConnectPubMedGoogle Scholar
  • 36 McCormack L, Stickland MH, Grant PJ. Plasminogen activator inhibitor-1 antigen concentrations during insulin and oral glucose tolerance tests in obese man. Fibrinolysis 1993; 7: 225-228
    PubMedGoogle Scholar
  • 37 Stiko-Rahm A, Wiman B, Hamsten A, Nilsson J. Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis 1990; 10: 1067-1073
    CrossrefPubMedGoogle Scholar
  • 38 Gough SC L, Grant PJ. The fibrinolytic system in diabetes mellitus. Diabet Med 1991; 8: 898-905
    CrossrefPubMedGoogle Scholar
  • 39 Kruithof EK O. Plasminogen activator inhibitor antigen. In ECAT assay procedures A manual of laboratory techniques. Jespersen J, Bertina RM, Haverkate F. eds Kluwer Academic Publishers; AA Dordrecht, Netherlands: 1992. ppl 51-53
    Google Scholar
  • 40 Panahloo A, Mohamed-Ali V, Lane A, Green F, Humphries S, Yudkin J. Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene. Diabetes 1995; 44: 37-42
    CrossrefPubMedGoogle Scholar
  • 41 Eriksson P, Kallin B, van’t Hooft F, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995; 92: 1851-1855
    CrossrefPubMedGoogle Scholar